Dentsply Sirona sold $38 million less in the three months ended June 30, yet kept roughly $2.50 more of every $100 in sales. Revenue fell 4.1% to $898 million, while gross margin rose from 52.4% to 54.9%. The dental-equipment maker managed the unusual trick of shrinking its top line and expanding the slice it retained.
The filing shows a margin improvement. Operating income swung from a $128 million loss to $82 million of profit, and net income moved from a $45 million loss to $37 million of profit. Shares still fell 4.2% at the latest close, to $13.19, though the supplied facts do not establish why.
The sales side remained weaker. Dentsply Sirona said lower volumes, unfavorable product mix, tariff-related expenses, and pricing pressure offset parts of the business that were growing. The company also spent more on research and development, which rose 21.6% to $45 million.
Management described the volume and pricing drag this way:
"Total net sales The net sales decrease on a constant currency basis for the three months ended June 30, 2026 was driven by lower volumes of OIS products in all regions primarily due to the absence of the Byte business in the Americas, lower volumes of CTS products in the Americas, lower volumes of EDS products in EMEA, and unfavorable pricing in EMEA and APAC across all segments."
Dentsply Sirona, 10-Q filed Aug. 6, 2026.
That is not a broad-based demand collapse in the language of the filing, but it is a list of specific pressures. The absence of the Byte business was one factor behind lower volumes.
There were offsets. Favorable pricing in the Americas, stronger APAC volumes for CTS, and new Wellspect products supported sales in parts of the portfolio:
"The decrease was partially offset by favorable pricing in the Americas, higher volumes of CTS products in APAC, and higher volumes of Wellspect products driven by new product introductions."
Dentsply Sirona, 10-Q filed Aug. 6, 2026.
The filing therefore leaves two operating facts in the same frame: the company sold fewer products, but gross profit edged up from $490 million to $493 million. The improvement below gross profit is larger still, though Dentsply Sirona does not assign the $210 million operating-income swing to one cause.
The balance sheet adds a second tension. Cash fell from $359 million to $239 million, even as inventory and accounts receivable declined modestly. For the six months ended June 30, cash used in investing activities increased, primarily because capital expenditures rose 88.2%. Profitability improved in the latest three months; the cash balance did not follow it upward.
One outside read-through is notably different: Henry Schein, a verified Dentsply Sirona customer representing 10.0% of its revenue, reported revenue growth of 6.3% on May 5. That does not explain Dentsply Sirona's decline, but it puts the company's lower volumes in context: a major customer was growing, while the supplier's own reported sales were not.
The unresolved number is 54.9%. Dentsply Sirona's next quarterly report will put that gross-margin percentage beside its next revenue figure, making the margin improvement and the smaller top line comparable again.
Source: Dentsply Sirona 10-Q filed Aug. 6, 2026.